| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5912397 | Multiple Sclerosis and Related Disorders | 2014 | 7 Pages |
Abstract
In AFFIRM, natalizumab treatment decreased the clinical severity of relapses and improved recovery from disability induced by relapses. These beneficial effects would limit the step-wise accumulation of disability.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Fred D. Lublin, Gary Cutter, Gavin Giovannoni, Amy Pace, Nolan R Campbell, Shibeshih Belachew,